TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07246304: A Preliminary Exploratory Clinical Study of TC-D101 in the Treatment of DLL3-Positive Relapsed/Refractory Primary Small Cell Lung Cancer

Sponsor: TCRCure Biopharma Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 24 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07246304 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07246304 Rescue Dossier →